Vical has filed over fifteen investigational new drug applications to conduct clinical trials and holds master files for manufacturing recombinant DNA products.
Vical has completed more than thirty clinical trials with recombinant DNA products. These Phase 1 – Phase 3 trials of vaccines or gene therapy products have been conducted in up to 15 countries.
Check back frequently for updates on future enrollments or connect with us through or connect with us on or .
Infectious Disease Vaccine Trials
Phase 3 Clinical Trial: ASP0113 Therapeutic Cytomegalovirus (CMV) Vaccine
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT).
For more information, please go to the NCT01877655 trial listing at ClinicalTrials.gov.
Phase 2 Clinical Trial: ASP0113 Therapeutic Cytomegalovirus (CMV) Vaccine
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor.
For more information, please go to the NCT01974206 trial listing at ClinicalTrials.gov.
Phase 1/2 Clinical Trial: Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults.
For more information, please go to the NCT02030301 trial listing at ClinicalTrials.gov.
Phase 1 Clinical Trial: VL-2397 Antifungal
A randomized, double-blind trial to evaluate safety, tolerability and pharmacokinetics of VL-2397 at single and multiple ascending doses in healthy volunteers.